Hexarelin (Growth Hormone Secretagogue) – Examorelin / HEX

Product Overview

Hexarelin is a highly advanced, synthetic hexapeptide recognized as one of the most potent Growth Hormone Releasing Peptides (GHRPs) available for research. Engineered with a specialized D-2-methyltryptophan substitution to enhance receptor binding affinity and proteolytic resistance, it yields massive, acute growth hormone elevations. Uniquely distinguishing itself from all other GHRPs, Hexarelin possesses a remarkable dual-action profile: it drives intense endocrine stimulation while simultaneously providing profound, GH-independent cardioprotective effects through specialized cardiac receptors.

Technical Specifications

• Molecular Formula: C47H58N12O6

• Molecular Weight: 887.04 g/mol

• CAS Number: 140703-51-1

• Sequence Profile: His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 (Features a modified tryptophan residue for superior enzymatic resistance and high-affinity receptor binding)

Mechanism of Action

Hexarelin operates through a distinct dual-receptor mechanism, making it highly valuable for interconnected endocrine and cardiovascular research:

• GHSR-1a Activation: Binds with exceptionally high affinity to the ghrelin receptor (GHSR-1a), stimulating acute growth hormone peaks that are 40-50% higher than GHRP-6 and 20-30% higher than GHRP-2 at equivalent doses.

• CD36 Scavenger Receptor Activation (Cardioprotection): Independent of its GH-releasing activity, Hexarelin binds to the CD36 scavenger receptor specifically located on cardiac myocytes. This triggers vital pro-survival signaling cascades, including the PI3K/Akt pathway and ERK1/2 phosphorylation, effectively protecting heart tissue from ischemia-induced apoptosis.

• Tachyphylaxis Dynamics: Due to its extreme potency, continuous administration induces significant receptor desensitization (tachyphylaxis) and increased somatostatin tone within 4 to 6 weeks, making it an ideal compound for studying receptor downregulation and acute, short-term pulse optimization.

• Anti-Fibrotic & Neuroprotective Signaling: Demonstrates the ability to suppress transforming growth factor beta (TGF-β) signaling, effectively reducing pathological collagen deposition and scar formation following injury, while also elevating anti-apoptotic proteins (like Bcl-2) in vulnerable neural tissues.

Primary Research Applications

Hexarelin is a premier compound for in vitro and animal model studies investigating:

• Acute, Maximum-Potency Growth Hormone Stimulation

• Myocardial Ischemia-Reperfusion Injury and Cardioprotection

• CD36 Receptor Pathways and Cardiac Cell Survival

• Anti-Fibrotic Activity and Extracellular Matrix Remodeling (Heart Failure Models)

• Cerebral Ischemia and Neurodegenerative Disease Modeling

Storage & Handling

For optimal long-term stability and structural integrity, store lyophilized powder securely at -4°F (-20°C). Reconstituted solutions should be kept refrigerated at 36°F to 46°F (2°C to 8°C) and utilized promptly in accordance with established laboratory cycling protocols.

⚠️ Important Disclaimer for Carbon Nova Labs Customers: All information provided is for educational and reference purposes only. Hexarelin is sold strictly for laboratory research use only. This compound is not approved by the FDA for human consumption, therapeutic use, or clinical application. Ensure compliance with all institutional safety protocols and consult qualified professionals before conducting research.